ATNM

Actinium Pharmaceuticals, Inc. (ATNM) - 10-Q Summary

Business Context and Reporting Period

Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology. Key pipeline assets include ATNM-400 (solid tumors), Actimab-A (hematology/solid tumors), Iomab-ACT (cell/gene therapy conditioning), and Iomab-B (bone marrow transplant conditioning).

Key Financial Metrics

Note: Revenue consists entirely of "Other revenue" from the recognition of a previously deferred license payment. No commercial product sales were recorded.

Material Changes vs. Prior Period

• Revenue Recognition: The Company recorded $35.0 million in revenue in Q2 2026 related to an upfront payment from Immedica Pharma AB (received in 2022). This amount was previously deferred due to uncertainty regarding regulatory approval. The Company concluded the constraint was removed as Immedica ceased pursuing approval in licensed territories.
• Profitability: The Company reported a net income of $27.9 million for Q2 2026, a reversal from a net loss of $6.9 million in Q2 2025. This is primarily driven by the $35.0 million revenue recognition.
• Expense Reduction: Operating expenses decreased year-over-year for the six-month period ($13.3M vs $24.1M). This reduction is largely due to a $9.0 million decrease in stock-based compensation expense, resulting from the cancellation of 4.9 million stock options in March 2025.
• Liquidity: Cash and cash equivalents decreased by approximately $11.5 million during the six months ended June 30, 2026, primarily due to operating cash outflows of $11.0 million.

Outlook, Risks, and Contingencies

• Listing Compliance: The Company received a notice from NYSE American regarding non-compliance with stockholders' equity requirements ($4.0M threshold) as of March 31, 2026. However, as of June 30, 2026, stockholders' equity stands at $30.3 million. The Company submitted a compliance plan and expects to regain technical compliance.
• Legal Proceedings: A putative securities class action lawsuit (In re Actinium Pharmaceuticals, Inc. Securities Litigation) alleges misrepresentations regarding the Iomab-B Phase 3 SIERRA Trial. The Company has moved to dismiss the complaint and is awaiting a court decision. Related derivative litigation is stayed pending the class action resolution.
• Regulatory Hurdles: The FDA has determined that the Phase 3 SIERRA trial data for Iomab-B is insufficient for a Biologics License Application (BLA). The FDA requires an additional randomized head-to-head Phase 3 trial and a dose optimization trial. The Company is seeking a strategic partner to fund these studies.
• Capital Resources: Management expects existing resources to fund operations for more than 12 months. The Company has an "At-the-Market" (ATM) sales agreement but has not sold shares in the current period.
• Government Shutdown Impact: A U.S. federal government shutdown from October 1 to November 12, 2025, disrupted operations at the FDA and NIH, potentially delaying clinical trials under the Company's CRADA with the National Cancer Institute (NCI).

Investor Verification Checklist

• Revenue Quality: Verify the accounting treatment of the $35.0 million Immedica revenue recognition and confirm no future commercial revenue is expected from this agreement.
• Listing Status: Monitor the status of the NYSE American compliance plan and confirm the removal of the ".BC" (below compliance) trading indicator.
• Legal Exposure: Track the court's decision on the motion to dismiss the securities class action lawsuit regarding the Iomab-B trial.
• Strategic Partnerships: Assess progress in securing a strategic partner to fund the additional FDA-required trials for Iomab-B.
• Cash Burn: Review the rate of cash consumption against the $36.5 million cash balance to validate the "more than 12 months" runway statement.